Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 3, 2003, Pages 298-302

  Justman, Jessica E ^a   Benning, Lorie ^b   Danoff, Ann ^c   Minkoff, Howard ^d   Levine, Alexandra ^e   Greenblatt, Ruth M ^f   Weber, Kathleen ^g   Piessens, Eva ^h   Robison, Esther ⁱ   Anastos, Kathryn ^j  

^a BRONX LEBANON HOSPITAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Veterans Administration   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Jr Hospital of Cook County   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

more..

Author keywords

Diabetes mellitus; Endocrine; Epidemiology; Lipodystrophy; Natural history; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

DIDANOSINE; LAMIVUDINE; MEGESTROL; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELDERLY CARE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCREENING TEST; SELF REPORT; WEIGHT GAIN;

ADULT; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INTERVIEWS; MULTIVARIATE ANALYSIS; PROTEASE INHIBITORS; RISK FACTORS; UNITED STATES;

EID: 0037340734     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200303010-00009     Document Type: Article

References (18)

1. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory. June 21, 1997.
3. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12(Suppl):F167-73.
4. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(Suppl):F51-8.
6. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology 1998;9:117-25.
7. NHLBI Obesity Education Initiative Expert Panel. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Bethesda, 1998.
8. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care 1991;14: 639-48.
9. Stricker RB, Goldberg B. Weight gain associated with protease inhibitor therapy in HIV-infected patients. Res Virol 1998;149: 123-6.
10. Pernerstorfer-Schoen H, Schindler K, Parschalk B, et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 1999;13:2389-96.
11. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998;12:1645-51.
12. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84:1925-31.
13. Schwenk A, Kremer G, Comely O, et al. Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Nutrition 1999;15:453-7.
14. Lipton RB, Liao Y, Cao G, et al. Determinants of incident noninsulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol 1993;138:826-39.
15. CDC. Trends in the prevalence and incidence of self-reported diabetes mellitus - United States, 1980-1994. MWWR 1997;46: 1014-8.
16. Knowler WC, Bennett PH, Hamman RF, et al. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978;108:497-505.
17. Dever LL, Oruwari PA, Figueroa WE, et al. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother 2000;34:580-4.
18. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6.